Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry.
Marco SebastianiAndreina ManfrediFlorenzo IannoneElisa GremeseAlessandra BortoluzziEnnio Giulio FavalliChiara BazzaniFausto SalaffiEnrico FusaroRosario FotiChiara GiannittiRoberto CaporaliAlberto CauliGiulia CassoneGiuseppe LopalcoLuca PetriccaGiovanni LapadulaPublished in: Archives of rheumatology (2020)
Although ETA demonstrated a high persistence in biologic-naïve RA patients, about 15% of patients discontinued the treatment within 12 months. The presence of comorbidities and a combination therapy with csDMARDs other than MTX were the main factors for an early withdrawal of the drug.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- combination therapy
- ejection fraction
- newly diagnosed
- chronic kidney disease
- disease activity
- prognostic factors
- peritoneal dialysis
- emergency department
- escherichia coli
- systemic lupus erythematosus
- interstitial lung disease
- cystic fibrosis
- pseudomonas aeruginosa
- candida albicans